Elevated levels of lipoprotein-a (LP-a) are an independent risk factor for atherosclerosis and coronary artery disease (1-3). Lp-a levels in humans show extreme variations with values ranging from < lmg/dL to > 500 mg/dL. The distribution in the population is skewed with the highest frquency at levels < 10 mg/dL. Individuals with plasma L p a levels above 20-30 mg/dL have a two to three fold higher risk for atherosclerotic disease..
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Lp-a consist of low-density-lipoprotein-like particles in which a high-molecular weight glycoprotein apolipoprotein-a (apo-a) is linked to apolipprotein B through a disulphide bond. Apo-a has strong homology with plasminogen and it has been suggested that one mechanism by which apo-a exerts its pathological effect is by inhibition of plasminogen activation. This could result in an inhibition of fibrinolysis and also stimulate proliferation of smooth muscle cells in the arterial wall by blocking the activation of latent transforming growth factor B ( 4 3 .
Apo-a is secreted by the liver (6); however, it is not known whether apo-a is secreted as a complex with a p B in lipoprotein parhcles or as a free protein. Nor is there any information about the intracellular events in the synthesis and transit of apo-a. This is due in part to the lack of a well established animal model for such studies. Although apo-a occurs in hedgehog (7) and preliminary studies suggest it is also in rabbit liver and plasma (8) it is not yet clear whether the protein behaves in the same way, or has the same functions, in these animals as in humans or primates.
In the present investigation we have used human liver samples to determine whether apo-a is linked to apo-B in hepatocytes. Two ELISA were developed:(i) a competition assay, in which Lp-a standard (Immuno Ltd) was immobilised in wells of microtitre plates. A limiting amount of sheep antihuman Lp-a (Immuno-Ltd) was added together with either a known amount of L p a standard (for competition curve) or an aliquot of unknown sample (serum or solubilised liver homogenate). The bound antibody was determined using anti-sheep IgG coupled to alkaline phosphatase: and (ii) a capture-sandwich-assay in which anti-Lp-a (Immuno Ltd) was immobilised in the wells of microtitre plates at a dilution chosen to give maximum binding of the highest Lp-a standard. Lp-a standards or unknown samples (serum or solubilised liver homogenates) were added. An anti-human-apo-B monoclonal antibody (MAC131 or MAC128 see ref 9) , was then added and this was determined using anti-rat IgG linked to alkaline phosphatase. Thus, the first ELISA measures total apo-a and the second ELISA measures apo-B attached to apo-a. The second ELISA was also modified by using an anti-human apoa monoclonal antibody (Boerhinger) as a second antibody to check that apo-a in solubilised liver homogenates bound to the well under the conditions of the assay.
Apo-a was detected at similar levels in four different human liver homogenates using either the competition ELISA or the capture ELISA with anti-apo-a as the second antibody; however, the levels of apo-B which mbound with apo-a in the capture ELISA were undetectable (Table 1) .
TABm 1
Apo-a levels in human liver measured using three different ELISA.
apo-a (ug/g liver)

Assay1
Assay2 Assay3 These results demonstrate that more that the apo-a in human liver is not complexed with apo-B. This suggests that apo-a is secreted by the liver and rapidly complexes with apo-B in LDL in the circulation. This observation is consistent with reports that baboon hepatocytes and livers of transgenic mice secrete apo-a in the free form (10, 1 I).
